
Louis Chesler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1361384/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Challenges to curing primary brain tumours. Nature Reviews Clinical Oncology, 2019, 16, 509-520.	12.5	540
2	Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats Journal of Clinical Investigation, 1996, 98, 671-679.	3.9	286
3	The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma. Cancer Cell, 2012, 22, 117-130.	7.7	270
4	Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. Journal of Cellular Physiology, 1994, 160, 194-202.	2.0	267
5	Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. Cancer Cell, 2013, 24, 75-89.	7.7	240
6	Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma. Cancer Research, 2006, 66, 8139-8146.	0.4	186
7	Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. Cancer Cell, 2012, 21, 601-613.	7.7	177
8	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 2015, 27, 72-84.	7.7	165
9	Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. Nature Genetics, 2018, 50, 515-523.	9.4	163
10	Pleiotropic role for <i>MYCN</i> in medulloblastoma. Genes and Development, 2010, 24, 1059-1072.	2.7	146
11	Structural basis of N-Myc binding by Aurora-A and its destabilization by kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13726-13731.	3.3	130
12	New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK. Clinical Cancer Research, 2013, 19, 5814-5821.	3.2	119
13	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium. Journal of Clinical Oncology, 2021, 39, 2859-2871.	0.8	101
14	CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research, 2012, 18, 5650-5661.	3.2	84
15	Metabolic engineering against the arginine microenvironment enhances CAR-T cell proliferation and therapeutic activity. Blood, 2020, 136, 1155-1160.	0.6	84
16	The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma. Science Signaling, 2014, 7, ra102.	1.6	80
17	The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes <i>MYCN</i> -Amplified Neuroblastoma <i>In Vivo</i> . Molecular Cancer Therapeutics, 2011, 10, 2115-2123.	1.9	79
18	Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity. Cancer Research, 2015, 75, 3043-3053.	0.4	78

#	Article	IF	CITATIONS
19	Subclonal reconstruction of tumors by using machine learning and population genetics. Nature Genetics, 2020, 52, 898-907.	9.4	77
20	Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nature Chemical Biology, 2021, 17, 954-963.	3.9	73
21	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <i>ALK</i> -mutated neuroblastoma. Oncotarget, 2014, 5, 8737-8749.	0.8	72
22	Association with Aurora-A Controls N-MYC-Dependent Promoter Escape and Pause Release of RNA Polymerase II during the Cell Cycle. Cell Reports, 2017, 21, 3483-3497.	2.9	71
23	Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. Clinical Cancer Research, 2012, 18, 2679-2686.	3.2	69
24	Malignant Progression and Blockade of Angiogenesis in a Murine Transgenic Model of Neuroblastoma. Cancer Research, 2007, 67, 9435-9442.	0.4	58
25	Implementation of mechanism of action biology-driven early drug development for children with cancer. European Journal of Cancer, 2016, 62, 124-131.	1.3	58
26	Chemotherapy-Induced Apoptosis in a Transgenic Model of Neuroblastoma Proceeds Through p53 Induction. Neoplasia, 2008, 10, 1268-IN34.	2.3	57
27	Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. Nature Communications, 2018, 9, 1126.	5.8	50
28	Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma. Cancer Research, 2019, 79, 611-624.	0.4	50
29	Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma. Nature Cancer, 2021, 2, 312-326.	5.7	50
30	Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 2015, 21, 5100-5109.	3.2	49
31	Genetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Seminars in Cancer Biology, 2011, 21, 245-255.	4.3	48
32	From class waivers to precision medicine in paediatric oncology. Lancet Oncology, The, 2017, 18, e394-e404.	5.1	45
33	Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. Journal of Medicinal Chemistry, 2019, 62, 2618-2637.	2.9	45
34	A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European Journal of Cancer, 2019, 121, 224-235.	1.3	44
35	<i>In Vivo</i> Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. Cancer Research, 2019, 79, 5382-5393.	0.4	42
36	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	1.3	42

#	Article	IF	CITATIONS
37	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget, 2016, 7, 57525-57544.	0.8	42
38	Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma. EBioMedicine, 2020, 59, 102971.	2.7	41
39	Identification of a neuronal transcription factor network involved in medulloblastoma development. Acta Neuropathologica Communications, 2013, 1, 35.	2.4	40
40	MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current Drug Targets, 2014, 15, 114-123.	1.0	40
41	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	3.9	40
42	Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography. Cancer Research, 2019, 79, 5874-5883.	0.4	35
43	Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. Journal of Cellular Biochemistry, 2007, 102, 1529-1541.	1.2	34
44	Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCNTransgenic Mouse Model of Neuroblastoma. Radiology, 2013, 266, 130-140.	3.6	33
45	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance. Cancer Research, 2016, 76, 3025-3035.	0.4	33
46	Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma. Nature Communications, 2022, 13, 1380.	5.8	32
47	miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs. PLoS ONE, 2011, 6, e28356.	1.1	30
48	Frequency and Prognostic Impact of <i>ALK</i> Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	0.8	30
49	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	2.5	28
50	Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic. Cancer Research, 2015, 75, 2770-2774.	0.4	26
51	Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma. Oncotarget, 2020, 11, 347-361.	0.8	26
52	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1–TGF-β–OTX2–SNAIL via PTEN inhibition. Brain, 2018, 141, 1300-1319.	3.7	22
53	Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Molecular Cancer, 2022, 21, .	7.9	21
54	Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Frontiers in Oncology, 2015, 5, 111.	1.3	20

#	Article	IF	CITATIONS
55	Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma. Molecular Oncology, 2016, 10, 538-552.	2.1	18
56	Thymosinâ€∲24 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Molecular Oncology, 2015, 9, 1484-1500.	2.1	17
57	MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma. Oncotarget, 2020, 11, 2141-2159.	0.8	17
58	18F-meta-fluorobenzylguanidine (18F-mFBG) to monitor changes in norepinephrine transporter expression in response to therapeutic intervention in neuroblastoma models. Scientific Reports, 2020, 10, 20918.	1.6	16
59	Intrinsic Susceptibility MRI Identifies Tumors with ALKF1174L Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma. PLoS ONE, 2014, 9, e92886.	1.1	16
60	Molecular and In Vivo Characterization of Cancer-Propagating Cells Derived from MYCN-Dependent Medulloblastoma. PLoS ONE, 2015, 10, e0119834.	1.1	16
61	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget, 2017, 8, 112036-112050.	0.8	16
62	Noninvasive MRI Native T1 Mapping Detects Response to <i>MYCN</i> -targeted Therapies in the Th- <i>MYCN</i> Model of Neuroblastoma. Cancer Research, 2020, 80, 3424-3435.	0.4	15
63	Preclinical transgenic and patientâ€derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. Brain Pathology, 2018, 28, 475-483.	2.1	14
64	MRI Imaging of the Hemodynamic Vasculature of Neuroblastoma Predicts Response to Antiangiogenic Treatment. Cancer Research, 2019, 79, 2978-2991.	0.4	13
65	The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 248.	1.1	13
66	Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours. European Journal of Cancer, 2022, 162, 209-220.	1.3	12
67	Biological Role of MYCN in Medulloblastoma: Novel Therapeutic Opportunities and Challenges Ahead. Frontiers in Oncology, 2021, 11, 694320.	1.3	11
68	Bromodomain and extra-terminalÂinhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE. European Journal of Cancer, 2021, 146, 115-124.	1.3	10
69	Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform. British Journal of Cancer, 2017, 117, 791-800.	2.9	9
70	Preclinical drug development for childhood cancer. Expert Opinion on Drug Discovery, 2011, 6, 49-64.	2.5	8
71	Immunoassays for the quantification of <scp>ALK</scp> and phosphorylated <scp>ALK</scp> support the evaluation of onâ€ŧarget <scp>ALK</scp> inhibitors in neuroblastoma. Molecular Oncology, 2017, 11, 996-1006.	2.1	6
72	Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT). Lung Cancer, 2021, 158, 151-155.	0.9	5

#	Article	IF	CITATIONS
73	Targeting MYCN and ALK in resistant and relapsing neuroblastoma. , 2019, 2, 803-812.		5
74	The biguanide polyamine analog verlindamycin promotes differentiation in neuroblastoma via induction of antizyme. Cancer Gene Therapy, 2022, 29, 940-950.	2.2	3
75	Paraneoplasia, cancer development and immunity: what are the connections?. Nature Reviews Cancer, 2014, 14, 447-448.	12.8	2
76	Neuroblastoma drug development: from lab bench to bedside?. Clinical Investigation, 2012, 2, 1157-1162.	0.0	0
77	EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM. Neuro-Oncology, 2018, 20, i66-i66.	0.6	0
78	Abstract 4189: Characterization of tumor progression and chemoresponse in a novel transgenic mouse model of neuroblastoma (TH-MYCN) using magnetic resonance imaging. , 2010, , .		0
79	Abstract 4757: The ALK-F1174L mutation accelerates MYCN-driven tumorigenesis in a murine transgenic neuroblastoma model. , 2011, , .		0
80	Abstract 4345: AZD8055, a combined TORC1/TORC2 inhibitor regulates Mycn protein expression and prevents neuroblastoma growth in vitro and in vivo. , 2011, , .		0
81	Abstract 3451: Interactions between N-myc and Sox9 promote medulloblastoma and determine cell fate decisions in cerebellar neural stem cells. , 2011, , .		0
82	Abstract 1426: MiRNA expression profiling of the murine GTML medulloblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. , 2012, , .		0
83	Abstract IA13: Targeting the dependence of N-Myc on interaction with Aurora-A with small molecules. , 2013, , .		0
84	Abstract B75: Defining the antitumor activity and sensitivity profiles of BET inhibitors in neuroblastoma. , 2014, , .		0
85	MBRS-57. IDENTIFICATION OF MYC-DEPENDENT THERAPEUTIC VULNERABILITIES FOR TARGETING GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii407-iii408.	0.6	0